

# Peter Foley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/426706/publications.pdf>

Version: 2024-02-01

52  
papers

3,847  
citations

218677

26  
h-index

254184

43  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3549  
citing authors

#	ARTICLE	IF	CITATIONS
1	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	3.0	30
2	Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (<sc>SUSTAIN</sc> study). <i>Australasian Journal of Dermatology</i> , 2022, 63, 303-311.	0.7	4
3	Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00402.	1.3	45
4	POS1031...LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 787-788.	0.9	0
5	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1357-1372.	3.0	19
6	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.5	36
7	Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital. <i>Dermatologic Therapy</i> , 2021, 34, e15128.	1.7	2
8	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 617-623.	2.2	10
9	Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative. <i>Australasian Journal of Dermatology</i> , 2020, 61, 9-22.	0.7	12
10	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	1.2	71
11	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	6.7	24
12	Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry. <i>Australasian Journal of Dermatology</i> , 2020, 61, 380-382.	0.7	3
13	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	3.0	40
14	Dermatologist attitudes toward ciclosporin use in atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-3.	2.2	2
15	Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltimMa1 and UltimMa2 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2830-2838.	2.4	46
16	Psoriasis and cancer. An Australian/New Zealand narrative. <i>Australasian Journal of Dermatology</i> , 2019, 60, 12-18.	0.7	21
17	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2437-2446.e1.	0.7	70
18	FRI0435...INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
19	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Phase III VOYAGE 1 and VOYAGE 2 Studies. American Journal of Clinical Dermatology, 2019, 20, 155-164.	6.7	37
20	Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1940-1949.	2.4	62
21	Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australasian Journal of Dermatology, 2018, 59, 86-100.	0.7	67
22	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. British Journal of Dermatology, 2018, 178, 132-139.	1.5	57
23	Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study. Journal of Sexual Medicine, 2018, 15, 1645-1652.	0.6	34
24	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. New England Journal of Medicine, 2018, 379, 1313-1321.	27.0	301
25	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet, The, 2018, 392, 650-661.	13.7	457
26	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. JAMA Dermatology, 2018, 154, 676.	4.1	90
27	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology, 2017, 76, 110-131.	1.2	554
28	Structured Expert Consensus on Actinic Keratosis: Treatment Algorithm Focusing on Daylight PDT. Journal of Cutaneous Medicine and Surgery, 2017, 21, 3S-16S.	1.2	33
29	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 2287-2303.	13.7	884
30	Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER 3. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 477-482.	2.4	71
31	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal of the American Academy of Dermatology, 2017, 76, 1093-1102.	1.2	110
32	Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2017, 177, 1562-1574.	1.5	68
33	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 498-506.	2.4	28
34	Adherence to topical therapies in actinic keratosis: A literature review. Journal of Dermatological Treatment, 2016, 27, 538-545.	2.2	14
35	Current landscape for treatment of advanced basal cell carcinoma. Australasian Journal of Dermatology, 2015, 56, 1-7.	0.7	14
36	Current and Future Oral Systemic Therapies for Psoriasis. Dermatologic Clinics, 2015, 33, 91-109.	1.7	26

#	ARTICLE	IF	CITATIONS
37	Physician perceptions and experience of current treatment in actinic keratosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 298-306.	2.4	23
38	Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2466-2469.	0.7	131
39	A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes. <i>Journal of Drugs in Dermatology</i> , 2011, 10, 1432-8.	0.8	21
40	Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. <i>International Journal of Dermatology</i> , 2009, 48, 1236-1245.	1.0	77
41	Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access program. <i>International Journal of Dermatology</i> , 2009, 48, 1376-1384.	1.0	0
42	Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. <i>Australasian Journal of Dermatology</i> , 2005, 46, S8-S10.	0.7	5
43	Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. <i>Australasian Journal of Dermatology</i> , 2005, 46, S8-S10.	0.7	4
44	Practical aspects of methyl aminolaevulinate photodynamic therapy. <i>Australasian Journal of Dermatology</i> , 2005, 46, S12-S13.	0.7	0
45	Methyl aminolaevulinate photodynamic therapy in practice: Treatment protocol. <i>Australasian Journal of Dermatology</i> , 2005, 46, S14-S14.	0.7	0
46	Methyl aminolaevulinate photodynamic therapy in practice: Treatment protocol. <i>Australasian Journal of Dermatology</i> , 2005, 46, S14.	0.7	0
47	Practical aspects of methyl aminolaevulinate photodynamic therapy. <i>Australasian Journal of Dermatology</i> , 2005, 46, S12-S13.	0.7	0
48	Practical aspects of methyl aminolaevulinate photodynamic therapy. <i>Australasian Journal of Dermatology</i> , 2005, 46 Suppl 3, S12-3; discussion S23-5.	0.7	0
49	Methyl aminolaevulinate photodynamic therapy in practice: treatment protocol. <i>Australasian Journal of Dermatology</i> , 2005, 46 Suppl 3, S14; discussion S23-5.	0.7	0
50	The Frequency of Common Skin Conditions in Preschool-aged Children in Australia. <i>Archives of Dermatology</i> , 2003, 139, 318-22.	1.4	71
51	The frequency of common skin conditions in preschool-age children in Australia: atopic dermatitis. <i>Archives of Dermatology</i> , 2001, 137, 293-300.	1.4	43
52	The frequency of reactions to sunscreens: results of a longitudinal population-based study on the regular use of sunscreens in Australia. <i>British Journal of Dermatology</i> , 1993, 128, 512-518.	1.5	130